Abstract
Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1)-the one EBV antigen that is expressed in all EBV-associated malignancies-has long been thought to go undetected by the cell-mediated immune system. However, recent studies show that EBNA1 can be presented to both CD4+ and CD8+ T cells, making it a potential new target for immunotherapy of EBV-related cancers.
| Original language | English |
|---|---|
| Pages (from-to) | 1301-1304 |
| Number of pages | 4 |
| Journal | Journal of Experimental Medicine |
| Volume | 199 |
| Issue number | 10 |
| DOIs | |
| State | Published - 17 May 2004 |
| Externally published | Yes |